Azenta (AZNT) Plummets 22% Amid Q1 Earnings Miss and Revenue Decline

[Para 1: The Lead] Azenta Therapeutics (AZNT) shares closed 22% lower on February 4, 2026, following a Q1 2026 earnings report that missed by $0.07 per share, with revenue down 18% year-over-year to $39.8 million. [Para 2: Supporting details & Context] The company cited reduced biologics sales and pricing pressures as reasons for the shortfall. Management attributed the decline to a delay in the approval of its lead product candidate, AZ-102, with a new estimated timeline of late 2026. The stock has underperformed the broader biotech sector this year, reflecting broader challenges in drug development and reimbursement.